Ebola vaccine 'highly effective' trial should continue

July 31 -- Merck & Co.'s vaccine for Ebola is "highly effective," according to an interim analysis from a panel of experts who recommended that a late-stage trial should continue. Bloomberg's Drew Armstrong reports on "Market Makers."